Chairman of the Board
Mr. Bihl has served on the Board since March 2008. He is an experienced executive with more than 30 years in leadership of global healthcare businesses including a broad base of operational, financial, and senior executive positions. Mr. Bihl is currently the CEO of Bioventus LLC, a global provider of ortho biologic products, effective December 2, 2013. He served as a director on the board of Greatbatch Inc., now Integer, from 2011 to December 2015, and joined the board of Nuvectra Inc., in February 2016, where he serves as Chairman of the Human Resources and Compensation Committee. Mr. Bihl was Group President of American Medical Systems (“AMS”), a subsidiary of Endo Pharmaceuticals, in Minneapolis, Minnesota. From 2008 to 2011, Mr. Bihl was the President and Chief Executive Officer of AMS. From 2000 to 2007, Mr. Bihl served in various senior leadership positions at Bayer Healthcare Diagnostics Division including Vice President of Finance, Senior Vice President of Business Planning and Administration, and President, Diagnostics Division. Subsequently, he was Chief Executive Officer of Siemens DX upon the acquisition of Bayer’s Diagnostics Division by Siemens AG.
Dr. Walker joined Spectral as President and CEO in April 2001. Previously, he held the position of COO of the Toronto General Hospital, and was Surgeon in Chief and Vice President of the Surgical Directorate of the University Hospital Network. Dr. Walker was an active Vascular Surgeon and the Director of the Intensive Care Program, and Professor of Medicine and Laboratory Medicine at the University of Toronto.
A pioneer in the area of endotoxin and its role in sepsis, and the co-inventor of the Endotoxin Activity Assay (EAA™), Dr. Walker is a frequent participant at leading sepsis and critical care conferences, has been a keynote speaker at symposiums focusing on the role of endotoxin in sepsis, and is the author of over 100 scientific publications. He received his M.D. from the University of Western Ontario, his Ph.D. from the Salgrenska University of Göteborg, Sweden, and is a graduate of the Advanced Management Program from Harvard School of Business.
Mr. Giese has served on the Board since March 2010 and is President of Queensbury Ventures Inc. Mr. Giese was President, Chief Executive Officer and a director of Medwell Capital Corp. from 1999 to 2015. Mr. Giese has over 25 years of corporate leadership experience as a Director, Chief Executive Officer and Chief Financial Officer, with 20 years’ experience in biotech. He was a founder of BioMS Medical Corp., which received the international Scripps award for its technology licensing deal with Eli Lilly, and was named Biotech Company of the Year in Canada in 2008. He has been a member of the board of directors of BioAlberta, an advisory member of the Institute of Corporate Directors (Canada) 28 and has received awards for entrepreneurship from BioAlberta and Ernst & Young. Mr. Giese has a B.A. (economics), a law degree and an M.B.A.
Jun Hayakawa received his master in Organic Chemistry at Keio University in 1990 and joined Toray Industries the very same year. In his 28 years with the company, he was responsible for medicinal chemistry of opioid compounds; invented Remitch (relief for a complication of kidney and liver failure); responsible for R&D management and licensing and business development for pharmaceutical products. As of April 2018, he is currently responsible for all business alliances and licenses in both pharmaceutical and medical device departments.
Mr. Herrera has served on the Board since September 2006. He is a experienced global healthcare executive with more than 40 years of experience. Mr. Herrera is the Chairman, CEO and founder of Altan Pharma Ltd, a global specialty hospital pharmaceuticals company, and was formerly the Chairman and founder of Pinnacle Biologics Inc. Previously, Mr. Herrera spent 24 years at Abbott Laboratories, serving as Senior Vice President, International Operations and President of Abbott International. In this role, he was accountable for international commercial operations including sales and marketing of pharmaceutical, nutritional and hospital products in markets outside the U.S. Mr. Herrera received a B.A. in industrial economics from the Universidad del Valle, Colombia and his M.B.A. from the Kellogg Graduate School of Management at Northwestern University.
Mr. Herrera is also member of the Board of Trustees of the National Multiple Sclerosis Society, Illinois Chapter.
Mr. Stevens has served on the Board since September 2014. Mr. Stevens brings over 20 years of experience in the capital markets and investment industry to the Company. He is currently the President of GS Investment Corp and was Managing Director of Westerkirk Capital Corp., both private investment management companies. He has held senior roles in investment banking and private equity and has a successful track record of value creation for shareholders. Mr. Stevens’ educational background includes an M.B.A from the Harvard University Graduate School of Business Administration.
135 The West Mall , Unit 2 • Toronto, Ontario • M9C 1C2 Canada
Tel: 1.416.626.3233 • Toll Free: 1.888.426.4264 • Fax: 1.416.626.7383